Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

Femme Homme

| Pays :
| Organes :
| Spécialités :

Extrait

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy drugs kill cancer cells more directly. This study will evaluate: - How bevacizumab, given with chemotherapy before surgery, and then bevacizumab given alone after surgery, will affect locally advanced breast tumors - Side effects from adding bevacizumab to chemotherapy - Whether adding bevacizumab to chemotherapy for breast cancer will affect the heart - If receiving bevacizumab will have any effect on how patients recover from surgery - Side effects of the combinations of drugs used in this study

Critère d'inclusion

Breast Cancer

Liens

nct
ictrp

Kusajili – Centralise les essais cliniques mondiaux

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast...